EUVIMEDEUVIMED entdecken
Open Access

HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver

Mouad Edderkaoui, Omer H M Elmadbouh, Adrian Lim, Yan Ou, Dina Hauptschein, Ankita Guha, Abdo Darwish, Vinicius F Calsavara, Ramachandran Murali, Neil Bhowmick, Arsen Osipov, Angela J Mathison und 3 weitere

International Journal of Biological Sciences · 24.10.2025 · 21 (15) · 6907-6925

DOI: 10.7150/ijbs.102132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, erschienen am 24.10.2025. Verfasst von Mouad Edderkaoui und 14 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center (CSMC), Los Angeles, Californ…. Hauptthemen laut MEDLINE: Histone Deacetylases, Pancreatic Neoplasms, Adaptor Proteins, Signal Transducing, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of human malignancy, and there is an urgency to develop more effective therapy. We previously showed that Metavert, a dual inhibitor of glycogen synthase kinase 3-beta (GSK-3β) and histone deacetylases (HDACs) prevents pancreatic ductal adenocarcinoma (PDAC) metastasis. In this study, we investigated the mechanisms that mediate metastasis and the roles of GSK-3β, HDACs, and Yes-associated protein (YAP) in this process. We found that HDAC4 and YAP are highly expressed in PDAC from patients with rapid disease progression and metastasis compared to those with prolonged recurrence-free survival. Pan-HDAC inhibition decreases metastasis in the splenic PDAC metastatic mouse model. Inhibition of HDAC4 reduces migration of cancer cells and decreases the mRNA and protein levels of transcription factor MYB Proto-Oncogene Like 1 (MybL1) and YAP. Mechanistic studies show that HDAC4 regulates transcription of YAP through up-regulating MybL1 expression. Comparable results were observed in colon and prostate cancers. ATAC-seq studies show that inhibition of HDAC4 causes chromatin remodeling in the YAP promoter region and reduces accessibility to the binding sites of multiple transcription factors, including those of MybL1. Pharmacological or molecular inhibition of YAP significantly decreases PDAC metastasis in vivo. Imaging Mass Cytometry (IMC) reveals no significant changes in immune cells, but a notable shift in the distribution patterns of cancer-associated hepatic stellate cells in the metastatic niche, when YAP is ablated in the cancer cells. The results demonstrate a novel metastasis-driving cell signaling pathway mediated by the functional interaction between HDAC4 and MybL1, which regulates YAP expression and metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone DeacetylasesPancreatic NeoplasmsAdaptor Proteins, Signal TransducingLiver NeoplasmsRepressor ProteinsTranscription FactorsTrans-ActivatorsHumansAnimalsMiceCell Line, TumorSignal TransductionYAP-Signaling ProteinsProto-Oncogene MasCarcinoma, Pancreatic DuctalGene Expression Regulation, Neoplastic

Substanzen

Histone DeacetylasesHDAC4 protein, humanYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingMAS1 protein, humanProto-Oncogene MasRepressor ProteinsTranscription FactorsTrans-ActivatorsYAP1 protein, human

Autor:innen und Institutionen

  • Departments of Medicine and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center (CSMC), Los Angeles, California, USA.
  • Department of Medicine, UCLA, California, USA.
  • David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Department of Internal Medicine, Creighton University Health Education Alliance, Phoenix, AZ, USA.
  • Cedars-Sinai Medical Center, Biostatistics Shared Resource, Department of Computational Biomedicine, Los Angeles, California, USA.
  • Department of Biomedical Sciences, Research Division of Immunology, CSMC, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Edderkaoui, M., Elmadbouh, O. H. M., Lim, A., Ou, Y., Hauptschein, D., Guha, A., Darwish, A., Calsavara, V. F., Murali, R., Bhowmick, N., Osipov, A., Mathison, A. J., Urrutia, R., Wang, Q., & Pandol, S. J. (2025). HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver. International Journal of Biological Sciences, 21(15), 6907-6925. https://doi.org/10.7150/ijbs.102132

Vancouver

Edderkaoui M, Elmadbouh OHM, Lim A, Ou Y, Hauptschein D, Guha A, et al. HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver. International Journal of Biological Sciences. 2025;21(15):6907-6925. doi:10.7150/ijbs.102132

BibTeX
@article{Edderkaoui2025,
  author = {Edderkaoui, Mouad and Elmadbouh, Omer H M and Lim, Adrian and Ou, Yan and Hauptschein, Dina and Guha, Ankita and Darwish, Abdo and Calsavara, Vinicius F and Murali, Ramachandran and Bhowmick, Neil and Osipov, Arsen and Mathison, Angela J and Urrutia, Raul and Wang, Qiang and Pandol, Stephen J},
  title = {HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver},
  journal = {International Journal of Biological Sciences},
  year = {2025},
  volume = {21},
  number = {15},
  pages = {6907--6925},
  doi = {10.7150/ijbs.102132}
}
Kostenlos starten →